The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus

Luke D. Jasenosky, Cristhian Cadena, Chad E. Mire, Viktoriya Borisevich, Viraga Haridas, Shahin Ranjbar, Aya Nambu, Sina Bavari, Veronica Soloveva, Supriya Sadukhan, Gail H. Cassell, Thomas W. Geisbert, Sun Hur, Anne E. Goldfeld

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Here, we show that the US Food and Drug Administration-approved oral drug nitazoxanide (NTZ) broadly amplifies the host innate immune response to viruses and inhibits Ebola virus (EBOV) replication. We find that NTZ enhances retinoic-acid-inducible protein I (RIG-I)-like-receptor, mitochondrial antiviral signaling protein, interferon regulatory factor 3, and interferon activities and induces transcription of the antiviral phosphatase GADD34. NTZ significantly inhibits EBOV replication in human cells through its effects on RIG-I and protein kinase R (PKR), suggesting that it counteracts EBOV VP35 protein's ability to block RIG-I and PKR sensing of EBOV. NTZ also inhibits a second negative-strand RNA virus, vesicular stomatitis virus (VSV), through RIG-I and GADD34, but not PKR, consistent with VSV's distinct host innate immune evasion mechanisms. Thus, NTZ counteracts varied virus-specific immune evasion strategies by generally enhancing the RNA sensing and interferon axis that is triggered by foreign cytoplasmic RNA exposure, and holds promise as an oral therapy against EBOV.

Original languageEnglish (US)
Pages (from-to)1279-1290
Number of pages12
JournaliScience
Volume19
DOIs
StatePublished - Sep 27 2019

Fingerprint

nitazoxanide
Ebolavirus
Antiviral Agents
Protein Kinases
Immune Evasion
Pharmaceutical Preparations
Virus Replication
Viruses
Interferons
Interferon Regulatory Factor-3
RNA
Vesicular Stomatitis
RNA Viruses
United States Food and Drug Administration
Tretinoin
Phosphoric Monoester Hydrolases
Innate Immunity
Proteins

Keywords

  • Immune Response
  • Mechanism of Action
  • Pathogenic Organism
  • Viral Microbiology

ASJC Scopus subject areas

  • General

Cite this

Jasenosky, L. D., Cadena, C., Mire, C. E., Borisevich, V., Haridas, V., Ranjbar, S., ... Goldfeld, A. E. (2019). The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus. iScience, 19, 1279-1290. https://doi.org/10.1016/j.isci.2019.07.003

The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus. / Jasenosky, Luke D.; Cadena, Cristhian; Mire, Chad E.; Borisevich, Viktoriya; Haridas, Viraga; Ranjbar, Shahin; Nambu, Aya; Bavari, Sina; Soloveva, Veronica; Sadukhan, Supriya; Cassell, Gail H.; Geisbert, Thomas W.; Hur, Sun; Goldfeld, Anne E.

In: iScience, Vol. 19, 27.09.2019, p. 1279-1290.

Research output: Contribution to journalArticle

Jasenosky, LD, Cadena, C, Mire, CE, Borisevich, V, Haridas, V, Ranjbar, S, Nambu, A, Bavari, S, Soloveva, V, Sadukhan, S, Cassell, GH, Geisbert, TW, Hur, S & Goldfeld, AE 2019, 'The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus', iScience, vol. 19, pp. 1279-1290. https://doi.org/10.1016/j.isci.2019.07.003
Jasenosky, Luke D. ; Cadena, Cristhian ; Mire, Chad E. ; Borisevich, Viktoriya ; Haridas, Viraga ; Ranjbar, Shahin ; Nambu, Aya ; Bavari, Sina ; Soloveva, Veronica ; Sadukhan, Supriya ; Cassell, Gail H. ; Geisbert, Thomas W. ; Hur, Sun ; Goldfeld, Anne E. / The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus. In: iScience. 2019 ; Vol. 19. pp. 1279-1290.
@article{125728750470434ca42563541baf7b00,
title = "The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus",
abstract = "Here, we show that the US Food and Drug Administration-approved oral drug nitazoxanide (NTZ) broadly amplifies the host innate immune response to viruses and inhibits Ebola virus (EBOV) replication. We find that NTZ enhances retinoic-acid-inducible protein I (RIG-I)-like-receptor, mitochondrial antiviral signaling protein, interferon regulatory factor 3, and interferon activities and induces transcription of the antiviral phosphatase GADD34. NTZ significantly inhibits EBOV replication in human cells through its effects on RIG-I and protein kinase R (PKR), suggesting that it counteracts EBOV VP35 protein's ability to block RIG-I and PKR sensing of EBOV. NTZ also inhibits a second negative-strand RNA virus, vesicular stomatitis virus (VSV), through RIG-I and GADD34, but not PKR, consistent with VSV's distinct host innate immune evasion mechanisms. Thus, NTZ counteracts varied virus-specific immune evasion strategies by generally enhancing the RNA sensing and interferon axis that is triggered by foreign cytoplasmic RNA exposure, and holds promise as an oral therapy against EBOV.",
keywords = "Immune Response, Mechanism of Action, Pathogenic Organism, Viral Microbiology",
author = "Jasenosky, {Luke D.} and Cristhian Cadena and Mire, {Chad E.} and Viktoriya Borisevich and Viraga Haridas and Shahin Ranjbar and Aya Nambu and Sina Bavari and Veronica Soloveva and Supriya Sadukhan and Cassell, {Gail H.} and Geisbert, {Thomas W.} and Sun Hur and Goldfeld, {Anne E.}",
year = "2019",
month = "9",
day = "27",
doi = "10.1016/j.isci.2019.07.003",
language = "English (US)",
volume = "19",
pages = "1279--1290",
journal = "iScience",
issn = "2589-0042",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus

AU - Jasenosky, Luke D.

AU - Cadena, Cristhian

AU - Mire, Chad E.

AU - Borisevich, Viktoriya

AU - Haridas, Viraga

AU - Ranjbar, Shahin

AU - Nambu, Aya

AU - Bavari, Sina

AU - Soloveva, Veronica

AU - Sadukhan, Supriya

AU - Cassell, Gail H.

AU - Geisbert, Thomas W.

AU - Hur, Sun

AU - Goldfeld, Anne E.

PY - 2019/9/27

Y1 - 2019/9/27

N2 - Here, we show that the US Food and Drug Administration-approved oral drug nitazoxanide (NTZ) broadly amplifies the host innate immune response to viruses and inhibits Ebola virus (EBOV) replication. We find that NTZ enhances retinoic-acid-inducible protein I (RIG-I)-like-receptor, mitochondrial antiviral signaling protein, interferon regulatory factor 3, and interferon activities and induces transcription of the antiviral phosphatase GADD34. NTZ significantly inhibits EBOV replication in human cells through its effects on RIG-I and protein kinase R (PKR), suggesting that it counteracts EBOV VP35 protein's ability to block RIG-I and PKR sensing of EBOV. NTZ also inhibits a second negative-strand RNA virus, vesicular stomatitis virus (VSV), through RIG-I and GADD34, but not PKR, consistent with VSV's distinct host innate immune evasion mechanisms. Thus, NTZ counteracts varied virus-specific immune evasion strategies by generally enhancing the RNA sensing and interferon axis that is triggered by foreign cytoplasmic RNA exposure, and holds promise as an oral therapy against EBOV.

AB - Here, we show that the US Food and Drug Administration-approved oral drug nitazoxanide (NTZ) broadly amplifies the host innate immune response to viruses and inhibits Ebola virus (EBOV) replication. We find that NTZ enhances retinoic-acid-inducible protein I (RIG-I)-like-receptor, mitochondrial antiviral signaling protein, interferon regulatory factor 3, and interferon activities and induces transcription of the antiviral phosphatase GADD34. NTZ significantly inhibits EBOV replication in human cells through its effects on RIG-I and protein kinase R (PKR), suggesting that it counteracts EBOV VP35 protein's ability to block RIG-I and PKR sensing of EBOV. NTZ also inhibits a second negative-strand RNA virus, vesicular stomatitis virus (VSV), through RIG-I and GADD34, but not PKR, consistent with VSV's distinct host innate immune evasion mechanisms. Thus, NTZ counteracts varied virus-specific immune evasion strategies by generally enhancing the RNA sensing and interferon axis that is triggered by foreign cytoplasmic RNA exposure, and holds promise as an oral therapy against EBOV.

KW - Immune Response

KW - Mechanism of Action

KW - Pathogenic Organism

KW - Viral Microbiology

UR - http://www.scopus.com/inward/record.url?scp=85072573249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072573249&partnerID=8YFLogxK

U2 - 10.1016/j.isci.2019.07.003

DO - 10.1016/j.isci.2019.07.003

M3 - Article

AN - SCOPUS:85072573249

VL - 19

SP - 1279

EP - 1290

JO - iScience

JF - iScience

SN - 2589-0042

ER -